News
CASI
2.650
-1.49%
-0.040
Casi Pharmaceuticals files $200M mixed securities shelf
TipRanks · 16h ago
BRIEF-Casi Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $200 Million- SEC Filing
Reuters · 16h ago
CASI Pharmaceuticals Faces Evomela® License Termination Dispute
TipRanks · 5d ago
Weekly Report: what happened at CASI last week (1209-1213)?
Weekly Report · 5d ago
Weekly Report: what happened at CASI last week (1202-1206)?
Weekly Report · 12/09 11:03
Weekly Report: what happened at CASI last week (1125-1129)?
Weekly Report · 12/02 11:03
Weekly Report: what happened at CASI last week (1118-1122)?
Weekly Report · 11/25 10:56
Weekly Report: what happened at CASI last week (1111-1115)?
Weekly Report · 11/18 10:54
Berkshire reveals stake in Domino’s, Alibaba reports mixed Q2: Morning Buzz
TipRanks · 11/15 17:00
CASI Pharmaceuticals’ Mixed Third-Quarter Performance in 2024
TipRanks · 11/15 14:00
Casi Pharmaceuticals reports Q3 EPS (55c) vs. (35c) last year
TipRanks · 11/15 13:10
CASI Pharmaceuticals reports Q3 results
Seeking Alpha · 11/15 13:06
Earnings Scheduled For November 14, 2024
Benzinga · 11/14 08:32
Here's the major earnings before the open tomorrow
Seeking Alpha · 11/13 23:00
CASI Pharmaceuticals Q3 Earnings Preview
Seeking Alpha · 11/13 17:20
Weekly Report: what happened at CASI last week (1104-1108)?
Weekly Report · 11/11 11:05
Weekly Report: what happened at CASI last week (1028-1101)?
Weekly Report · 11/04 11:03
Weekly Report: what happened at CASI last week (1021-1025)?
Weekly Report · 10/28 10:56
Casi Pharmaceuticals receives CTA approval from China NMPA for CID-103
TipRanks · 10/24 12:55
Weekly Report: what happened at CASI last week (1014-1018)?
Weekly Report · 10/21 10:53
More
Webull provides a variety of real-time CASI stock news. You can receive the latest news about Casi Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.